{"product_id":"elekta-pestle-analysis","title":"Elekta PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our targeted PESTLE Analysis of Elekta—uncover how political regulation, healthcare economics, and emerging technologies will shape its trajectory and inform smarter decisions; buy the full report for actionable insights, editable charts, and strategic recommendations ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Funding Priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational healthcare budgets drive procurement of high-cost devices like linear accelerators; OECD countries spent a median 9.2% of GDP on health in 2024, shaping capital allocations for radiotherapy purchases.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, over 30 governments announced oncology infrastructure boosts—EU Recovery\/Resilience funds and UK NHS capital plans committed €6–€12 billion combined—to clear screening and treatment backlogs.\u003c\/p\u003e\n\u003cp\u003eElekta’s order book and long-cycle installations depend heavily on state-funded programs; public-sector contracts represented about 55% of Elekta’s 2024 equipment revenue, underpinning multi-year install pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing trade tensions between the US, China and EU have raised tariffs and export controls that disrupt MedTech supply chains; for Elekta, 2024 component cost inflation averaged 6–9% in sourced precision parts, per industry data.\u003c\/p\u003e\n\u003cp\u003eElekta faces complex licensing and customs delays for key radiotherapy components, with potential tariff exposure up to 5–12% on certain imports affecting gross margins.\u003c\/p\u003e\n\u003cp\u003eStrategic localization—Elekta expanded manufacturing in Sweden, the US and India in 2023–24—reducing cross-border exposure and shortening lead times by an estimated 20–30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Cancer Control Plans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMany countries now mandate expanded radiotherapy in National Cancer Control Plans; WHO estimates 50%+ of low-middle income countries report RTT shortages, driving capital investment programs. Governments in UK, Germany, China and Saudi Arabia offer targeted grants\/subsidies—examples include UK NHS capital funds ~£2bn (2024–25) and Saudi Vision oncology funding—supporting uptake of MR-Linac systems. Elekta times market entries to align with these roadmaps to capture share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-Private Partnerships in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments are signing multi-year public-private partnerships to modernize oncology infrastructure; Elekta reported 2024 service and software contract backlog contributing roughly SEK 6.2bn, reflecting multi-year revenue visibility.\u003c\/p\u003e\n\u003cp\u003eElekta supplies integrated hardware, software and maintenance under national programs, increasing share-of-wallet with bundled offerings and lowering procurement churn.\u003c\/p\u003e\n\u003cp\u003eThese political arrangements secure predictable cash flows, deepen integration into national health systems, and supported Elekta’s 2024 recurring revenue growth of about 14% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSEK 6.2bn service\/software backlog (2024)\u003c\/li\u003e\n\u003cli\u003eRecurring revenue +14% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts → stable cash flow and system integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical initiatives like the EU Medical Device Regulation convergence and ICH-style talks aim to harmonize standards, shortening approval cycles; global alignment could cut time-to-market by an estimated 20% for complex devices.\u003c\/p\u003e\n\u003cp\u003eElekta gains as faster approvals accelerate revenue recognition—the company reported SEK 9.5bn in FY2024 orders, where quicker launches can boost cash flow and margin expansion.\u003c\/p\u003e\n\u003cp\u003eStill, geopolitical shifts and regulatory revisions can force rapid compliance spend increases and process changes, risking program delays and additional CAPEX.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHarmonization may reduce approval time ~20%\u003c\/li\u003e\n\u003cli\u003eFY2024 orders SEK 9.5bn linked to faster commercialization\u003c\/li\u003e\n\u003cli\u003eRegulatory volatility increases compliance costs and CAPEX risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta buoyed by public oncology spend; SEK 6.2bn backlog, recurring rev +14%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eState health budgets and oncology programs drive Elekta demand; public contracts were ~55% of 2024 equipment revenue and service\/software backlog SEK 6.2bn. OECD median health spend 9.2% GDP (2024); FY2024 orders SEK 9.5bn; recurring revenue +14% YoY. Trade tensions raised component inflation 6–9% (2024); localization cut lead times ~20–30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic share of equipment rev\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\/software backlog\u003c\/td\u003e\n\u003ctd\u003eSEK 6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY orders\u003c\/td\u003e\n\u003ctd\u003eSEK 9.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev growth\u003c\/td\u003e\n\u003ctd\u003e+14% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent inflation\u003c\/td\u003e\n\u003ctd\u003e6–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces—Political, Economic, Social, Technological, Environmental, and Legal—specifically impact Elekta’s competitive position, product adoption, and regulatory compliance across global oncology and neurosurgery markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Elekta PESTLE summary that distills regulatory, technological, economic, and geopolitical factors into a single slide-ready page for fast stakeholder alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflation and Cost Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 lifted input costs for medical device makers; global producer price inflation peaked near 12% in 2022 and remained elevated at ~4–6% in 2024, pressuring Elekta’s margins via higher raw material and specialist labor expenses. Elekta responded with rigorous cost-efficiency programs, targeting double-digit annual savings and reducing operating costs by ~5% year-over-year in 2024. The firm’s ability to pass costs to customers hinges on the clinical necessity and value of its oncology systems, with cancer-care capital budgets showing modest growth of ~3% annually in many developed markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift from fee-for-service to value-based reimbursement pushes hospitals to favor technologies that lower total cost of care; Elekta highlights studies showing its precision radiotherapy can reduce local recurrence rates by up to 15% and cut downstream costs—supporting reimbursement negotiations as payers tie payments to outcomes. In 2024, value-based contracts covered roughly 37% of US Medicare beneficiaries, directly impacting demand for high-end oncology equipment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic expansion in Southeast Asia and Latin America, where GDP growth averaged about 4.5% in 2024 and middle-class populations grew by ~3% annually, creates demand for first-generation radiotherapy systems that Elekta can install cost-effectively.\u003c\/p\u003e\n\u003cp\u003eRising middle classes—projected to add ~200 million people in these regions by 2030—drive demand for accessible cancer care; Elekta’s scalable systems address budgets of public hospitals with constrained capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Expenditure Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigh global interest rates and tighter credit have reduced CAPEX by private healthcare, with hospital equipment investment down ~6% in 2024 in Europe; this pressures demand for Elekta’s high-cost radiotherapy systems.\u003c\/p\u003e\n\u003cp\u003eElekta expanded leasing and SaaS offerings—leasing revenue up ~18% in FY2024—lowering initial outlays and preserving order flow.\u003c\/p\u003e\n\u003cp\u003eThis economic strategy mitigates sales volatility: equipment orders grew 3% YoY in H1 2025 despite constrained CAPEX.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeasing\/SaaS up ~18% FY2024\u003c\/li\u003e\n\u003cli\u003eHealthcare CAPEX -6% Europe 2024\u003c\/li\u003e\n\u003cli\u003eOrders +3% YoY H1 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a Swedish medtech with \u0026gt;70% sales outside Sweden, Elekta is exposed to SEK\/USD, SEK\/EUR and SEK\/CNY swings; a 10% SEK appreciation versus USD in 2024 could reduce reported SEK revenues materially and compress margins given global pricing.\u003c\/p\u003e\n\u003cp\u003eThe group reported hedging instruments covering a significant portion of forecast FX flows—cash flow hedges and forwards—helping smooth FX translation; in 2024 Elekta noted FX impacts on operating income of tens of MSEK.\u003c\/p\u003e\n\u003cp\u003eLarge currency moves can erode price competitiveness in key markets (US, EU, China), so active hedging and regional pricing adjustments are central to managing this economic risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% sales outside Sweden\u003c\/li\u003e\n\u003cli\u003e10% SEK move materially affects SEK revenues\u003c\/li\u003e\n\u003cli\u003eHedging via forwards\/cash flow hedges reduces volatility\u003c\/li\u003e\n\u003cli\u003e2024 FX swung operating income by tens of MSEK\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta offsets inflation and FX pain with opex cuts, SaaS growth and rising orders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation raised input costs (PPI ~4–6% in 2024), pressuring margins; Elekta cut opex ~5% YoY and grew leasing\/SaaS +18% FY2024 to offset lower CAPEX (Europe healthcare investment -6% 2024). Value-based care (37% Medicare in VBC 2024) favors cost-saving radiotherapy; orders +3% YoY H1 2025. FX exposure (~70% sales outside Sweden) caused 2024 operating income swings of tens of MSEK despite hedges.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPI\u003c\/td\u003e\n\u003ctd\u003e4–6% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpex reduction\u003c\/td\u003e\n\u003ctd\u003e~5% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeasing\/SaaS\u003c\/td\u003e\n\u003ctd\u003e+18% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare CAPEX EU\u003c\/td\u003e\n\u003ctd\u003e-6% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrders\u003c\/td\u003e\n\u003ctd\u003e+3% YoY H1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBC coverage (US)\u003c\/td\u003e\n\u003ctd\u003e37% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales outside SE\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact\u003c\/td\u003e\n\u003ctd\u003etens of MSEK (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eElekta PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Elekta PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. This file contains the same content, structure, and professional layout visible in the preview with no placeholders or teasers. After checkout you’ll instantly download this final, ready-to-use document. Everything displayed here is part of the finished product you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751678128505,"sku":"elekta-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/elekta-pestle-analysis.png?v=1772233987","url":"https:\/\/matrixbcg.com\/products\/elekta-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}